Loading clinical trials...
Loading clinical trials...
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wei Zhao
Collaborators
NCT07085065 · Pain Management, Anxiety, and more
NCT02634294 · Hematological Neoplasms, Recurrence
NCT02223052 · Hematological Neoplasms, Non-Hodgkin's Lymphoma, and more
NCT00440765 · Multiple Myeloma, Hematological Neoplasms
NCT00410696 · Hematological Neoplasms, Tumors
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions